JPWO2018229630A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2018229630A5 JPWO2018229630A5 JP2020517619A JP2020517619A JPWO2018229630A5 JP WO2018229630 A5 JPWO2018229630 A5 JP WO2018229630A5 JP 2020517619 A JP2020517619 A JP 2020517619A JP 2020517619 A JP2020517619 A JP 2020517619A JP WO2018229630 A5 JPWO2018229630 A5 JP WO2018229630A5
- Authority
- JP
- Japan
- Prior art keywords
- cardiovascular
- disease
- pharmaceutical composition
- patient
- canagliflozin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000271 cardiovascular Effects 0.000 claims description 189
- 229960001713 canagliflozin Drugs 0.000 claims description 74
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 claims description 74
- 208000008787 Cardiovascular Disease Diseases 0.000 claims description 71
- 230000034994 death Effects 0.000 claims description 57
- 231100000517 death Toxicity 0.000 claims description 57
- 208000006011 Stroke Diseases 0.000 claims description 51
- 208000010125 Myocardial Infarction Diseases 0.000 claims description 50
- 201000010099 disease Diseases 0.000 claims description 42
- 206010007554 Cardiac failure Diseases 0.000 claims description 33
- 206010019280 Heart failure Diseases 0.000 claims description 33
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims description 32
- 208000008589 Obesity Diseases 0.000 claims description 29
- 206010020772 Hypertension Diseases 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 24
- 206010001580 Albuminuria Diseases 0.000 claims description 24
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 24
- 235000020824 obesity Nutrition 0.000 claims description 24
- 229940068196 placebo Drugs 0.000 claims description 22
- 239000000902 placebo Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- 206010002383 Angina pectoris Diseases 0.000 claims description 16
- 206010027525 Microalbuminuria Diseases 0.000 claims description 16
- 201000008739 coronary artery disease Diseases 0.000 claims description 15
- 150000003626 triacylglycerols Chemical class 0.000 claims description 14
- 229940107161 Cholesterol Drugs 0.000 claims description 12
- 102000004877 Insulin Human genes 0.000 claims description 12
- 108090001061 Insulin Proteins 0.000 claims description 12
- 238000005259 measurement Methods 0.000 claims description 12
- 206010003119 Arrhythmia Diseases 0.000 claims description 11
- 206010007521 Cardiac arrhythmias Diseases 0.000 claims description 11
- 206010062060 Hyperlipidaemia Diseases 0.000 claims description 11
- 206010034636 Peripheral vascular disease Diseases 0.000 claims description 9
- 201000001084 cerebrovascular disease Diseases 0.000 claims description 9
- 230000035488 systolic blood pressure Effects 0.000 claims description 9
- 229940109239 Creatinine Drugs 0.000 claims description 8
- 208000007888 Sinus Tachycardia Diseases 0.000 claims description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 8
- 201000011528 vascular disease Diseases 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- 102100001249 ALB Human genes 0.000 claims description 6
- 101710027066 ALB Proteins 0.000 claims description 6
- 208000005846 Cardiomyopathy Diseases 0.000 claims description 6
- 229940050528 albumin Drugs 0.000 claims description 6
- 201000008031 cardiomyopathy Diseases 0.000 claims description 6
- 230000002354 daily Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 5
- 108091005979 glycated hemoglobin Proteins 0.000 claims description 5
- 201000001421 hyperglycemia Diseases 0.000 claims description 5
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 4
- 229960003105 Metformin Drugs 0.000 claims description 4
- 230000003143 atherosclerotic Effects 0.000 claims description 4
- 201000002053 hypertensive heart disease Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 4
- 230000001225 therapeutic Effects 0.000 claims description 4
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims description 3
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims description 3
- 101710042131 GCG Proteins 0.000 claims description 3
- 102100003818 GCG Human genes 0.000 claims description 3
- 208000001083 Kidney Disease Diseases 0.000 claims description 3
- 208000003067 Myocardial Ischemia Diseases 0.000 claims description 3
- 230000001396 anti-anti-diuretic Effects 0.000 claims description 3
- 239000003472 antidiabetic agent Substances 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 230000036454 renin-angiotensin system Effects 0.000 claims description 3
- 229940030606 DIURETICS Drugs 0.000 claims description 2
- 229940090121 Sulfonylureas for blood glucose lowering Drugs 0.000 claims 3
- 206010062198 Microangiopathy Diseases 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960004676 ANTITHROMBOTIC AGENTS Drugs 0.000 claims 1
- 101700039191 EGFR Proteins 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 206010029149 Nephropathy Diseases 0.000 claims 1
- 206010029151 Nephropathy Diseases 0.000 claims 1
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 1
- 206010062585 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 108009000466 Renin Angiotensin Aldosterone System (RAAS) Proteins 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010038932 Retinopathy Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 238000002266 amputation Methods 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940090127 blood glucose lowering Alpha glucosidase inhibitors Drugs 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 description 46
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 45
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 45
- 210000004369 Blood Anatomy 0.000 description 33
- 239000008280 blood Substances 0.000 description 33
- 230000000268 renotropic Effects 0.000 description 33
- 230000000694 effects Effects 0.000 description 24
- 206010012601 Diabetes mellitus Diseases 0.000 description 23
- 230000002411 adverse Effects 0.000 description 21
- 206010007559 Cardiac failure congestive Diseases 0.000 description 18
- 201000006233 congestive heart failure Diseases 0.000 description 18
- 230000001965 increased Effects 0.000 description 16
- 210000002216 Heart Anatomy 0.000 description 14
- 235000020828 fasting Nutrition 0.000 description 14
- 230000002265 prevention Effects 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- 206010022489 Insulin resistance Diseases 0.000 description 13
- 230000000747 cardiac effect Effects 0.000 description 13
- 230000000302 ischemic Effects 0.000 description 13
- 108060003412 GRP Proteins 0.000 description 12
- 102000015779 HDL Lipoproteins Human genes 0.000 description 12
- 239000000969 carrier Substances 0.000 description 12
- 230000002829 reduced Effects 0.000 description 12
- 230000036772 blood pressure Effects 0.000 description 11
- 210000002966 Serum Anatomy 0.000 description 10
- 230000024924 glomerular filtration Effects 0.000 description 10
- 208000007814 Unstable Angina Diseases 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000003937 drug carrier Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 206010003658 Atrial fibrillation Diseases 0.000 description 8
- 206010061255 Ischaemia Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000000004 hemodynamic Effects 0.000 description 8
- 230000000250 revascularization Effects 0.000 description 8
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 7
- 210000002381 Plasma Anatomy 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000002131 composite material Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 201000010238 heart disease Diseases 0.000 description 7
- 230000000051 modifying Effects 0.000 description 7
- 230000000291 postprandial Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010002388 Angina unstable Diseases 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 6
- 210000003734 Kidney Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000035487 diastolic blood pressure Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 description 5
- 208000001022 Morbid Obesity Diseases 0.000 description 5
- 206010033307 Overweight Diseases 0.000 description 5
- 208000001280 Prediabetic State Diseases 0.000 description 5
- 208000003663 Ventricular Fibrillation Diseases 0.000 description 5
- 206010047302 Ventricular tachycardia Diseases 0.000 description 5
- 238000002679 ablation Methods 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 230000002068 genetic Effects 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 235000020825 overweight Nutrition 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 201000009104 prediabetes syndrome Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000000391 smoking Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000002485 urinary Effects 0.000 description 5
- 208000004981 Coronary Disease Diseases 0.000 description 4
- 210000004351 Coronary Vessels Anatomy 0.000 description 4
- 206010072736 Rheumatic disease Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000001058 adult Effects 0.000 description 4
- 201000001320 atherosclerosis Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 230000002093 peripheral Effects 0.000 description 4
- 201000002911 peripheral artery disease Diseases 0.000 description 4
- 230000002335 preservative Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000000552 rheumatic Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 230000002459 sustained Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 210000004204 Blood Vessels Anatomy 0.000 description 3
- 208000006170 Carotid Stenosis Diseases 0.000 description 3
- 206010007687 Carotid artery stenosis Diseases 0.000 description 3
- 208000007322 Death, Sudden, Cardiac Diseases 0.000 description 3
- 206010012758 Diastolic hypertension Diseases 0.000 description 3
- 208000002907 Heart Valve Disease Diseases 0.000 description 3
- 210000003709 Heart Valves Anatomy 0.000 description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N Inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 229940029339 Inulin Drugs 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 210000004165 Myocardium Anatomy 0.000 description 3
- 206010072563 Peripheral artery stenosis Diseases 0.000 description 3
- 208000010378 Pulmonary Embolism Diseases 0.000 description 3
- 206010038444 Renal failure chronic Diseases 0.000 description 3
- 206010061481 Renal injury Diseases 0.000 description 3
- 206010049418 Sudden cardiac death Diseases 0.000 description 3
- 206010042957 Systolic hypertension Diseases 0.000 description 3
- 208000001871 Tachycardia Diseases 0.000 description 3
- 229940116362 Tragacanth Drugs 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 201000000522 chronic kidney disease Diseases 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 201000010046 dilated cardiomyopathy Diseases 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- -1 elixirs Substances 0.000 description 3
- 230000001747 exhibiting Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000001434 glomerular Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000003451 hyperinsulinaemic Effects 0.000 description 3
- 201000008980 hyperinsulinism Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000546 pharmaceutic aid Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 201000010874 syndrome Diseases 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 208000007474 Aortic Aneurysm Diseases 0.000 description 2
- 210000001367 Arteries Anatomy 0.000 description 2
- 206010007515 Cardiac arrest Diseases 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- 208000009863 Chronic Kidney Failure Diseases 0.000 description 2
- 208000001636 Diabetic Neuropathy Diseases 0.000 description 2
- 206010012680 Diabetic neuropathy Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 206010018987 Haemorrhage Diseases 0.000 description 2
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 210000001624 Hip Anatomy 0.000 description 2
- 206010020871 Hypertrophic cardiomyopathy Diseases 0.000 description 2
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 240000008962 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 206010038428 Renal disease Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 206010042772 Syncope Diseases 0.000 description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 2
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 101700069624 aksF Proteins 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000007681 bariatric surgery Methods 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007887 coronary angioplasty Methods 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 230000002349 favourable Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 230000002641 glycemic Effects 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003979 granulating agent Substances 0.000 description 2
- 101710022949 icd Proteins 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000002757 inflammatory Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002642 intravenous therapy Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 230000002085 persistent Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000000069 prophylaxis Effects 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 200000000009 stenosis Diseases 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000000576 supplementary Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000001052 transient Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229940030600 ANTIHYPERTENSIVES Drugs 0.000 description 1
- 101700065507 APOB Proteins 0.000 description 1
- 102100001085 APOB Human genes 0.000 description 1
- 206010000891 Acute myocardial infarction Diseases 0.000 description 1
- 206010001029 Acute pulmonary oedema Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 210000003423 Ankle Anatomy 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- 206010002895 Aortic dissection Diseases 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003668 Atrial tachycardia Diseases 0.000 description 1
- 206010003885 Azotaemia Diseases 0.000 description 1
- ISAOCJYIOMOJEB-UHFFFAOYSA-N Benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 1
- 229960002130 Benzoin Drugs 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 210000002665 Bowman Capsule Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 108010082834 Brain Natriuretic Peptide Proteins 0.000 description 1
- 102000025380 C-Reactive Protein Human genes 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 208000006017 Cardiac Tamponade Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 206010007625 Cardiogenic shock Diseases 0.000 description 1
- 208000004672 Cardiovascular Infections Diseases 0.000 description 1
- 210000001715 Carotid Arteries Anatomy 0.000 description 1
- 206010008479 Chest pain Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathy Diseases 0.000 description 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 description 1
- 206010061835 Diabetic nephropathy Diseases 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N Diatrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014486 Elevated triglyceride Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 206010014665 Endocarditis Diseases 0.000 description 1
- 210000001174 Endocardium Anatomy 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 230000036081 Excretion rate Effects 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 229940012952 Fibrinogen Drugs 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 description 1
- 101700071595 GRZ1 Proteins 0.000 description 1
- 108009000020 Glucose Homeostasis Proteins 0.000 description 1
- 102000037828 Glucose transporter family Human genes 0.000 description 1
- 108091006272 Glucose transporter family Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010020993 Hypoglycaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010056997 Impaired fasting glucose Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 229940029378 Iothalamate Drugs 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102100001083 LPA Human genes 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000009856 Lung Disease Diseases 0.000 description 1
- 229940057948 Magnesium stearate Drugs 0.000 description 1
- 208000008466 Metabolic Disease Diseases 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 208000000418 Premature Cardiac Complexe Diseases 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 206010038436 Renal failure acute Diseases 0.000 description 1
- 208000004124 Rheumatic Heart Disease Diseases 0.000 description 1
- 102100016749 SLC5A2 Human genes 0.000 description 1
- 101710040674 SLC5A2 Proteins 0.000 description 1
- 229940080350 SODIUM STEARATE Drugs 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M Sodium stearate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 240000008975 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 235000008411 Sumatra benzointree Nutrition 0.000 description 1
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 1
- 206010049447 Tachyarrhythmia Diseases 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 208000009852 Uremia Diseases 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 208000004043 Venous Thromboembolism Diseases 0.000 description 1
- 101700078733 ZGLP1 Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 230000002058 anti-hyperglycaemic Effects 0.000 description 1
- 230000003276 anti-hypertensive Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000002051 biphasic Effects 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229940121115 canagliflozin 100 MG Drugs 0.000 description 1
- 229940121155 canagliflozin 300 MG Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000001447 compensatory Effects 0.000 description 1
- 201000003137 congenital heart disease Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 201000000057 coronary stenosis Diseases 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003205 diastolic Effects 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 230000001882 diuretic Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000001610 euglycemic Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 108010049074 hemoglobin B Proteins 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000003345 hyperglycaemic Effects 0.000 description 1
- 230000000910 hyperinsulinemic Effects 0.000 description 1
- 230000002218 hypoglycaemic Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000001019 normoglycemic Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000007888 peripheral angioplasty Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000013878 renal filtration Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000247 serious adverse effect Toxicity 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000153 supplemental Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023077544A JP2023113644A (ja) | 2017-06-12 | 2023-05-10 | ２型糖尿病の患者における心血管イベントの低減又は予防方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518547P | 2017-06-12 | 2017-06-12 | |
| US62/518,547 | 2017-06-12 | ||
| PCT/IB2018/054208 WO2018229630A1 (en) | 2017-06-12 | 2018-06-11 | Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077544A Division JP2023113644A (ja) | 2017-06-12 | 2023-05-10 | ２型糖尿病の患者における心血管イベントの低減又は予防方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523408A JP2020523408A (ja) | 2020-08-06 |
| JP2020523408A5 JP2020523408A5 (hu) | 2021-07-26 |
| JPWO2018229630A5 true JPWO2018229630A5 (hu) | 2022-09-27 |
Family
ID=62916717
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517619A Pending JP2020523408A (ja) | 2017-06-12 | 2018-06-11 | ２型糖尿病の患者における心血管イベントの低減又は予防方法 |
| JP2023077544A Pending JP2023113644A (ja) | 2017-06-12 | 2023-05-10 | ２型糖尿病の患者における心血管イベントの低減又は予防方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077544A Pending JP2023113644A (ja) | 2017-06-12 | 2023-05-10 | ２型糖尿病の患者における心血管イベントの低減又は予防方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20180353470A1 (hu) |
| EP (1) | EP3638250A1 (hu) |
| JP (2) | JP2020523408A (hu) |
| KR (1) | KR20200014406A (hu) |
| CN (1) | CN110740735A (hu) |
| AU (1) | AU2018283781B2 (hu) |
| BR (1) | BR112019026120A2 (hu) |
| CA (1) | CA3066874A1 (hu) |
| CO (1) | CO2019013940A2 (hu) |
| EA (1) | EA202090028A1 (hu) |
| IL (1) | IL271100A (hu) |
| MX (1) | MX2019014988A (hu) |
| TW (1) | TWI835735B (hu) |
| UA (1) | UA127987C2 (hu) |
| WO (1) | WO2018229630A1 (hu) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI827184B (zh) * | 2021-08-03 | 2023-12-21 | 國立政治大學 | 第2型糖尿病併發症的風險評估系統與方法 |
| CN117085009B (zh) * | 2023-10-20 | 2024-01-30 | 首都医科大学附属北京天坛医院 | 卡格列净对急性缺血性卒中的治疗作用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004260761B2 (en) | 2003-08-01 | 2008-01-31 | Mitsubishi Tanabe Pharma Corporation | Novel compounds having inhibitory activity against sodium-dependent transporter |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| EP2385374B2 (en) * | 2010-05-05 | 2018-02-28 | Zora Biosciences OY | Lipidomic biomarkers for atherosclerosis and cardiovascular disease |
| ES2836952T3 (es) * | 2010-05-11 | 2021-06-28 | Mitsubishi Tanabe Pharma Corp | Comprimidos que contienen canagliflozina |
| CA2812016A1 (en) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20160000816A1 (en) * | 2013-04-05 | 2016-01-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN113082021A (zh) * | 2014-01-31 | 2021-07-09 | 詹森药业有限公司 | 用于治疗和预防肾病和脂肪肝病的方法 |
| US20170071970A1 (en) * | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
-
2018
- 2018-06-08 TW TW107119774A patent/TWI835735B/zh active
- 2018-06-11 UA UAA202000168A patent/UA127987C2/uk unknown
- 2018-06-11 EA EA202090028A patent/EA202090028A1/ru unknown
- 2018-06-11 BR BR112019026120-6A patent/BR112019026120A2/pt unknown
- 2018-06-11 KR KR1020207000103A patent/KR20200014406A/ko not_active Application Discontinuation
- 2018-06-11 JP JP2020517619A patent/JP2020523408A/ja active Pending
- 2018-06-11 WO PCT/IB2018/054208 patent/WO2018229630A1/en active Application Filing
- 2018-06-11 CA CA3066874A patent/CA3066874A1/en active Pending
- 2018-06-11 US US16/004,607 patent/US20180353470A1/en not_active Abandoned
- 2018-06-11 MX MX2019014988A patent/MX2019014988A/es unknown
- 2018-06-11 AU AU2018283781A patent/AU2018283781B2/en active Active
- 2018-06-11 EP EP18740894.3A patent/EP3638250A1/en active Pending
- 2018-06-11 CN CN201880039211.2A patent/CN110740735A/zh active Pending
-
2019
- 2019-12-02 IL IL271100A patent/IL271100A/en unknown
- 2019-12-11 CO CONC2019/0013940A patent/CO2019013940A2/es unknown
-
2020
- 2020-09-15 US US17/021,370 patent/US20210000792A1/en active Pending
-
2023
- 2023-05-10 JP JP2023077544A patent/JP2023113644A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kimura et al. | JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome | |
| JP7020756B2 (ja) | 対象の心血管イベントのリスクを低減する方法 | |
| JP6672365B2 (ja) | エンパグリフロジンの治療的使用 | |
| JP2023001136A (ja) | エンパグリフロジンを含む医薬組成物及びその使用 | |
| JP2021534185A (ja) | スタチン治療対象における末梢動脈血行再建の必要性を低減する方法 | |
| JP2023113644A (ja) | ２型糖尿病の患者における心血管イベントの低減又は予防方法 | |
| EA022948B1 (ru) | Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью | |
| Sakai et al. | Effects of Sodium-Glucose Cotransporter 2 Inhibitor on Vascular Endothelial and Diastolic Function in Heart Failure With Preserved Ejection Fraction―Novel Prospective Cohort Study― | |
| RU2768283C2 (ru) | Семаглутид при сердечно-сосудистых состояниях | |
| TW202108134A (zh) | 利用達格列淨治療射血分率降低的心臟衰竭之方法 | |
| Wybraniec et al. | Contrast-induced acute kidney injury: the dark side of cardiac catheterization | |
| Wu et al. | SGLT2 Inhibitors: New Hope for the Treatment of Acute Myocardial Infarction? | |
| Sánchez et al. | Recommendations for the management of hyperkalemia in the emergency department | |
| JPWO2018229630A5 (hu) | ||
| JP2015512908A (ja) | 基礎インスリン療法 | |
| CN113613659A (zh) | 用于治疗患有慢性肾病的糖尿病患者的卡格列净 | |
| US20190343853A1 (en) | Methods of treating hypertension | |
| KEITH et al. | RECESSION OF NEURORETINOPATHY DURING THE COURSE OF MALIGNANT HYPERTENSION: Its Occurrence in Fifteen Patients Who Did Not Receive Directed Therapy | |
| Morillas et al. | Sodium-glucose co-transporter 2 inhibitors in acute heart failure: a review of the available evidence and practical guidance on clinical use | |
| Ilie et al. | The endocrine pancreas and diabetes mellitus | |
| Madjidova et al. | FEATURES OF BIGUANIDES IN COMBINATION THERAPY OF HYPERTENSION WITH METABOLIC SYNDROME | |
| Kavanagh | Antihypertensive drugs | |
| Urunbaeva et al. | STUDY OF THE HYPOGLYCEMIC AND CARDIOPROTECTIVE EFFECT OF EMPAGLIFLOZIN IN THERAPY OF PATIENTS WITH TYPE 2 DIABETES MELLITUS | |
| Akar et al. | Can SGLT2 Inhibitors be a Good Option in the Management of Resistant Hypertension in Diabetic Hypertensive Patients? | |
| Hasselbalch et al. | P1745 Routine blood tests are strong predictors of mortality among patients with suspected heart disease in the emergency department |